Research programme: Ebola virus infections and viral haemorrhagic fever therapeutics- Integrated BioTherapeutics

Drug Profile

Research programme: Ebola virus infections and viral haemorrhagic fever therapeutics- Integrated BioTherapeutics

Alternative Names: CA 45; Filovirus equine immunoglobulin; FVM 04; Pan-Ebola monoclonal antibodies - Integrated BioTherapeutics; Pan-Filovirus monoclonal antibodies - Integrated BioTherapeutics

Latest Information Update: 06 Apr 2017

Price : $50

At a glance

  • Originator Integrated BioTherapeutics
  • Developer Auburn University; Emergent BioSolutions; Integrated BioTherapeutics; United States Army Medical Research Institute of Infectious Diseases
  • Class Immunoglobulins; Monoclonal antibodies; Viral vaccines
  • Mechanism of Action Immunoglobulin modulators; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ebola virus infections; Viral haemorrhagic fevers
  • No development reported Marburg virus disease

Most Recent Events

  • 02 Mar 2017 Preclinical development for Ebola virus infections is ongoing USA
  • 15 Nov 2016 Integrated BioTherapeutics and Emergent BioSolutions agree to worldwide co-develop filovirus equine immunoglobulin for haemorrhagic fever from filovirus infection
  • 15 Nov 2016 Early research in Viral haemorrhagic fevers in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top